Patents matching “antagonist”

US 7524965

Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Theravance, Inc. · Granted Apr 28, 2009 · Expires Apr 23, 2029

US 7521041

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Apr 21, 2009 · Expires Apr 16, 2029

US 7507716

Method for treating pain with prolactin antagonists

The Board of Regents of the University of Texas System · Granted Mar 24, 2009 · Expires Mar 19, 2029

US 7501442

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Mar 10, 2009 · Expires Mar 5, 2029

US 7491736

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Feb 17, 2009 · Expires Feb 12, 2029

US 7482470

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Jan 27, 2009 · Expires Jan 22, 2029

US 7479562

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jan 20, 2009 · Expires Jan 15, 2029

US 7462625

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Dec 9, 2008 · Expires Dec 4, 2028

US 7459426

Methods of using IL-1 antagonists to treat autoinflammatory disease

REGENERON PHARMACEUTICALS, INC. · Granted Dec 2, 2008 · Expires Nov 27, 2028

US 7456199

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Nov 25, 2008 · Expires Nov 20, 2028

US 7456203

Muscarinic receptor antagonists

Theravance, Inc. · Granted Nov 25, 2008 · Expires Nov 20, 2028

US 7452865

Antagonistic analogs of GH RH (2003)

United States of America by Dept of Veterans Affairs · Granted Nov 18, 2008 · Expires Nov 13, 2028

US 7449182

Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

REGENERON PHARMACEUTICALS, INC. · Granted Nov 11, 2008 · Expires Nov 6, 2028

US 7446108

Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists

Neurocrine, Inc. · Granted Nov 4, 2008 · Expires Oct 30, 2028

US 7432304

Small molecule antagonists of Bcl-2 family proteins

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 7, 2008 · Expires Oct 2, 2028

US 7427630

Condensed N-heterocyclic compounds and their use as CRF receptor antagonists

Neurocrine Biosciences, Inc. · Granted Sep 23, 2008 · Expires Sep 18, 2028

US 7425329

Methods for treating bone cancer pain by administering a nerve growth factor antagonist

Regents of the University of Minnesota · Granted Sep 16, 2008 · Expires Sep 11, 2028

US 7419983

Gonadotropin-releasing hormone receptor antagonists and methods related thereto

Neurocrine Biosciences, Inc. · Granted Sep 2, 2008 · Expires Aug 28, 2028

US 7378108

Percutaneous absorption preparation of compound having angiotensin II antagonistic activity

Takeda Pharmaceutical Company Limited · Granted May 27, 2008 · Expires May 22, 2028

US 7365165

IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Apr 29, 2008 · Expires Apr 24, 2028

US 7361664

Vitamin D receptor antagonists and related compositions and methods of use

The United States of America, as represented by the Department of Health and Human Services · Granted Apr 22, 2008 · Expires Apr 17, 2028

US 7361350

Use of an IL-1 antagonist for treating arthritis

REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2008 · Expires Apr 17, 2028

US 7358222

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California · Granted Apr 15, 2008 · Expires Apr 10, 2028

US 7354579

Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028